Overview

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Status:
Recruiting

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). The primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Collaborators:

HIV Prevention Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Drug Abuse (NIDA)

Treatments:

Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Tenofovir